Who are olopatadine 0.2% ophthalmic solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bepreve, bepotastine besilate ophthalmic solution, Levocetirizine (drug), Cetirizine Dry Syrup, Cetirizine tablets, Olopatadine Nasal Spray.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olopatadine-0-2-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

olopatadine 0.2% ophthalmic solution — Competitive Intelligence Brief

olopatadine 0.2% ophthalmic solution (olopatadine 0.2% ophthalmic solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist. Area: Ophthalmology.

marketed H1-receptor antagonist H1-receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

olopatadine 0.2% ophthalmic solution (olopatadine 0.2% ophthalmic solution) — Allergan. Olopatadine blocks H1-receptors on ocular mast cells and other immune cells to reduce histamine-mediated itching and allergic inflammation in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
olopatadine 0.2% ophthalmic solution TARGET	olopatadine 0.2% ophthalmic solution	Allergan	marketed	H1-receptor antagonist	H1-receptor
Bepreve	BEPOTASTINE	Bausch Health	marketed	Histamine-1 Receptor Antagonist	H1-receptor, mast cells	2009-01-01
bepotastine besilate ophthalmic solution	bepotastine besilate ophthalmic solution	Bausch & Lomb Incorporated	marketed		H1-receptor, mast cells
Levocetirizine (drug)	Levocetirizine (drug)	UCB Pharma	marketed	H1-receptor antagonist (second-generation antihistamine)	H1-receptor
Cetirizine Dry Syrup	Cetirizine Dry Syrup	GlaxoSmithKline	phase 3	H1-receptor antagonist (second-generation antihistamine)	H1-receptor
Cetirizine tablets	Cetirizine tablets	UCB Pharma	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 receptor
Olopatadine Nasal Spray	Olopatadine Nasal Spray	ORA, Inc.	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist class)

Allergan · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Faes Farma, S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). olopatadine 0.2% ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/olopatadine-0-2-ophthalmic-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab